Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manish Jain

Clinical Cardiac Electrophysiology Concord, NC Medical Doctor

NPI 1962611657 CMS profile 180541

100 Medical Park Dr, Ste 210, Concord, NC 28025

Open in the dashboard

General payments

$126,891

692 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manish Jain of Concord, NC is reported in the CMS Open Payments database as having received $126,891 across 692 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,955 38
2024 General $8,425 114
2023 General $2,826 166
2022 General $4,851 68
2021 General $15,566 88
2020 General $17,838 60
2019 General $62,430 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manish Jain
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Manish Jain were reported at $14,955. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Manish Jain Clinical Cardiac Electrophysiology median Middle half National median
2019 $62,430 $2,361 $585–$8,260 $163
2020 $17,838 $993 $247–$4,351 $114
2021 $15,566 $1,185 $326–$4,739 $132
2022 $4,851 $2,073 $554–$6,789 $149
2023 $2,826 $2,568 $759–$8,159 $160
2024 $8,425 $2,557 $703–$7,403 $164
2025 $14,955 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $59,430 113 payments
  2. Janssen Pharmaceuticals, Inc $22,136 24 payments
  3. Kestra Medical Technology Services, Inc. $10,463 48 payments
  4. AltaThera Pharmaceuticals LLC $8,440 4 payments
  5. Abbott Laboratories $8,233 257 payments
  6. Medtronic Vascular, Inc. $5,456 53 payments
  7. Boston Scientific Corporation $5,289 91 payments
  8. Biotronik Inc. $4,797 25 payments
  9. Atricure, Inc. $997 18 payments
  10. Medtronic, Inc. $805 35 payments
  11. Other $846 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,500 58 payments
  2. Food and Beverage $17,810 579 payments
  3. Travel and Lodging $15,082 44 payments
  4. Consulting Fee $10,955 5 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,000 2 payments
  6. Honoraria $500 1 payment
  7. Education $44 3 payments
Products named General payments · program years 2019–2025
  1. LifeVest $59,430 113 payments
  2. XARELTO $22,136 24 payments
  3. Assure WCD Cardiology/Vascular Diseases $9,270 7 payments
  4. Sotalol Hydrochloride $8,440 4 payments
  5. CardioMEMS HF System $3,255 3 payments
  6. Arctic Front $2,199 21 payments
  7. Reveal LINQ $2,162 16 payments
  8. Assure WCD Cardiology $1,193 41 payments
  9. MICRA $1,025 13 payments
  10. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $997 18 payments
  11. Other $9,592 399 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,206

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$772,947

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

45.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 628 $590,289
Xarelto Rivaroxaban Brand 103 $96,208
Multaq Dronedarone Hcl Brand 43 $42,507
Dofetilide Generic 148 $17,775
Flecainide Acetate Generic 396 $16,030
Amiodarone Hcl Generic 228 $2,672
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 108 $1,953
Metoprolol Succinate Generic 112 $1,516
Sotalol Sotalol Hcl Brand 71 $1,272
Metoprolol Tartrate Generic 84 $490

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$225,567

Medicare's payments for the services billed

Medicare patients

2,881

Average age 77

Services billed

6,109

1,336 women, 1,545 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 57%
Ischemic heart disease 54%
Arthritis 49%
Heart failure 48%
Diabetes 40%
Chronic kidney disease 39%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $3,500
$3,500 71 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $17
$17 628 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

692 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record